Chemomab Therapeutics has announced that it has successfully completed its End-of-Phase 2 meeting with the FDA, aligning on the design of a single Phase 3 trial for its lead product candidate ...

--Ionis Pharmaceuticals, Inc. today announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and Drug Administration on ION582, an investigational medicine for ...

BOSTON, January 13, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...

“Alignment around a global Phase 3 study design for zorevunersen puts us one step closer to our goal of delivering the first disease-modifying medicine for the treatment of Dravet syndrome ...

Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel ...

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assessment for the design of a phase 3 trial assessing belzupacap sarotalocan, according to a ...

The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and ...